All Work

Jon C. Ogg

Morgan Stanley Sees Big Upside in Netflix

Morgan Stanley initiated coverage of Netflix with an Overweight rating in a shift of analyst coverage from an Equal Weight rating. Morgan Stanley also gave the stock a $500 price target.

Jon C. Ogg · 12 years ago

Consumer Prices Actually Hit the Fed’s Inflation Target

ThinkstockWhile the producer prices might have shown some fears of deflation, the Consumer Price Index (CPI) for May is showing an uptick of prices. The headline CPI saw a gain of 0.4%, higher than…

Jon C. Ogg · 12 years ago

Why Everyone, or Nobody, Would Want to Acquire Nuance

ThinkstockNuance Communications Inc. (NASDAQ: NUAN) owes its fortunes back to the days of Lernout & Hauspie in the 1990s. Now the independent speech recognition leader is seeing its shares surge on reports that the…

Jon C. Ogg · 12 years ago

Can BlackBerry Win With Earnings This Week?

Wikimedia CommonsBlackBerry Ltd. (NASDAQ: BBRY) remains on a path to a turnaround under new CEO John Chen. Or does it? Getting excited about anything at BlackBerry these days seems very hard to do, but…

Jon C. Ogg · 12 years ago

What to Expect From Yellen and the FOMC This Week

courtesy of the Federal ReserveOver the past week, U.S. and global financial markets have gone from a period of complacency to being worried about an outright civil war and uprising in Iraq. But now…

Jon C. Ogg · 12 years ago

Why Time Warner May Never End ‘Game of Thrones’

ThinkstockIf Home Box Office (HBO) has shown one thing, it is that it can create incredible loyalty for its cable channels by making its own shows. The hit series “Game of Thrones” followed the…

Jon C. Ogg · 12 years ago

Has Lululemon Lost All of Its Supporters?

ThinkstockLululemon Athletica Inc. (NASDAQ: LULU) is still in trouble after earnings. No one with any sanity was really expecting a good earnings report, but the problems of yesterday keep becoming the problems of tomorrow.…

Jon C. Ogg · 12 years ago

How the New Time Inc. Is Evaluated and Valued

ThinkstockTime Inc. (NYSE: TIME) is now out on its own, and the spin-off from Time Warner Inc. (NYSE: TWX) is now a week into being on its own. 24/7 Wall St. wanted to see what…

Jon C. Ogg · 12 years ago

The MannKind Lifeline Lights Up

MannKind is just about a month away from the FDA decision on Afrezza as the first inhalable insulin treatment for diabetes. Afrezza almost certainly will become a blockbuster drug if approved.

Jon C. Ogg · 12 years ago